1. Introduction {#s0005}
===============

Mutations in the homeobox transcription factor *ARX* are responsible for a wide spectrum of neurodevelopmental disorders extending from extremely severe neuronal migration defects resulting in three-layered lissencephaly (XLAG syndrome, MIM\#[300215](300215){#ir0005}), to mild forms of Intellectual Disability (ID) without apparent brain abnormalities, but with associated features of dystonia and epilepsy (reviewed in [@bb0145], [@bb0340], [@bb0265]). Although Arx expression in mouse has been reported in several developing structures including brain, pancreas, testes, heart, skeletal muscle and liver ([@bb0245]; [@bb0025]; [@bb0210]; [@bb0060]; [@bb0030]), the most striking consequences of *Arx* loss of function affect brain and testes, both in mice and humans ([@bb0035]; [@bb0210]; [@bb0070]; [@bb0235]). In the developing and adult rodent brain, Arx expression in telencephalic structures, particularly in populations of GABA-containing neurons, has been extensively described ([@bb0065]; [@bb0280]; [@bb0050]; [@bb0150]; [@bb0155]). Studies of the effects of *ARX* loss of function either in humans or in in mutant mice have shown that this gene plays multiple roles during development, most importantly in the generation and migration of GABAergic interneurons (see for review [@bb0145]), leading, when mutated, to a disorder of interneurons, called "interneuronopathy" ([@bb0205]; [@bb0295]). More recently, Arx has been shown to be also involved in the development of excitatory neurons ([@bb0155]; [@bb0020]; [@bb0055]; [@bb0345]) through its expression in cortical progenitors, thus explaining the microcephaly phenotype observed in knock-out mice and human XLAG patients ([@bb0035]; [@bb0210]).

Although the general steps of brain development are conserved between human and rodents, there are some differences, in particular concerning the number and complexity of GABAergic interneurons that greatly increase relatively to glutamatergic neurons during mammalian and particularly primate evolution ([@bb0305]). Since no detailed description of ARX expression in human brain has ever been performed, we decided to investigate human ARX expression using immunohistochemistry at different fetal stages as well as in an adult case. Then, to further investigate the role of ARX in brain development and function, we focused on the *in vivo* phenotypic characterization of the most frequent mutation found in this gene, *i.e.* a duplication of 24 base pairs (c.429_452dup24, noted dup24) leading to a polyalanine tract expansion, which is thought to result in a decreased amount of ARX protein ([@bb0215]) and/or the deregulation of a subset of ARX target genes (Friocourt and Dubos, unpublished data). This mutation results in a relatively mild phenotype that can be more deeply explored than very severe phenotypes such as XLAG syndrome, which are most often lethal shortly after birth. By clinically reviewing all affected patients identified in France over a five-year period (*i.e.* 27 patients from 12 different families), we recently described a very specific phenotype associated with this mutation ([@bb0085]). All *ARX* patients exhibited ID with no primary motor impairment, but with a very specific upper limb distal motor apraxia associated with a pathognomonic hand-grip. A spectrum of severity level is observed ranging from the milder form, exhibiting atypical handling and/or articulation impairment, to the most severe form, the so-called Partington syndrome, with major hand dystonia and/or oro-lingual apraxia. The particular "reach and grip" impairment was further characterized by kinematic analysis, and consisted of loss of preference for the index finger when gripping an object, major impairment of fourth finger deftness and lack of pronation movements. This lack of distal movement coordination was associated with the loss of independent digital dexterity, similarly to the distortion of individual finger movements and posture observed in Limb Kinetic Apraxia (LKA). These findings led us to suggest that the *ARX* dup24 mutation may be a developmental model for LKA ([@bb0085]).

In the present study, we performed for the first time a study of ARX expression at the protein level both during fetal human development and in an adult brain, as well as MRI morphometric analyses (1.5 T) on 13 *ARX* dup24 patients compared to 13 sex- and age-matched healthy controls using FreeSurfer software, a very powerful tool both for surface, in particular cortical thickness measurement at each point across the cortical mantle, and volumetric analyses ([@bb0095]; [@bb0130]; [@bb0125]; [@bb0135]; [@bb0190]; [@bb0330]). The goal of the present study was to find a potential neuro-anatomical distinctive pattern associated with this mutation of *ARX*, a gene highly expressed during neurodevelopment, that could help in explaining the specific developmental LKA observed in *ARX* dup24 patients.

2. Material and methods {#s0010}
=======================

2.1. Neuropathological studies {#s0015}
------------------------------

### 2.1.1. Patient selection {#s0020}

Thirteen fetal brains ranging from 13 to 40 weeks of gestation (WG) along with an adult case were selected ([Table 1](#t0005){ref-type="table"}). None of the studied cases displayed any particular medical familial history of neurological disease and all brains were macroscopically and microscopically free of detectable abnormalities. The brains used in this study belong to the collection which has been declared to the French Ministry of Health (collection number DC-2015-2468, cession number AC-2015-2467). This collection is located in the Pathology Laboratory, Rouen University hospital. For all selected cases, parents had given their consent for neuropathological studies of the foetuses following autopsy performed in agreement with the local ethic committee and in accordance with the French law. In each case, a complete autopsy had been performed. Cases who were suspected of central nervous system anomalies or who had been suspected of dying from neurologic causes were systematically excluded. Main causes of death were spontaneous death in single or twin pregnancies after premature rupture of membranes or chorioamnionitis (Supplementary Table 1).Table 1Semi-quantitative analysis of *ARX* expression in the developing central nervous system.Table 113--18 WG22--28 WG30--36 WG40 WGAdultTelencephalonMarginal zone/Layer I+++++++++++Cortical plate++++++++++++Intermediate zone++++++++0ventricular and subventricular zones++++++++NANAHippocampus++++++NANANAGanglionic eminences++++++++++++NACaudate nucleus++++++++++Putamen+++++++NAGlobus pallidus+++++++NASubstantia innominate, Basal nucleus of Meynert+++++++NADiencephalonPreoptic area+++++NANANAMedial and posterior hypothalamus++++++++NANAThalamic nuclei++++++++NANAAmygdala++++++NANANACerebellum00000[^2][^3][^4][^5][^6][^7]

Brain growth of fetal and neonatal cases was evaluated according to the criteria of ([@bb0175]). Macroscopic evaluation of brain maturation, in particular gyration, was performed according to the atlas of Feess-Higgins and Larroche ([@bb0120]). After fixation into a zinc-10% formalin buffer solution for one month, 7 μm paraffin embedded sections were stained using Haematoxylin-eosin and Cresyl Violet, which made it possible to confirm the absence of cerebral lesions. The morphology of all different brain structures studied was consistent with the age of the patients. Microscopic analysis of the different neuroanatomical structures was performed according to Bayer and Altman\'s atlas of human central nervous system development ([@bb0015]).

### 2.1.2. Immunohistochemical procedures {#s0025}

Five micrometer coronal sections were cut from formalin-fixed paraffin-embedded blocks, mounted on coated slides (Silanized Slides S 3003 Dako, Trappes, France) and dried overnight in a convection oven (37 °C). Sections were deparaffined in three baths of xylene and re-hydrated in a series of ethanol solutions. Induced epitope retrieval was performed by immersion in a citrate buffer solution pH 6 at 95--99 °C for 1 h. Slides were then rinsed in distilled water and left to cool down. Different pre-treatments and dilutions were tested to determine the optimal dilution (1/500) for the polyclonal anti-ARX antibody ([@bb0280]). Incubations were performed for 1 h at room temperature using the TECHMATE 500 system (Dakopatts, Trappes, France). After incubation, slides were processed by Labelled Streptavidin Biotin Method (LSAB) detection kit (Dakopatts). Peroxidase was visualized either using 3-3′ diaminobenzidine or amino-ethyl-carbazole. A negative control was obtained by omission of the primary antibody. The specificity of ARX labelling was further confirmed by the absence of staining in the cerebellum, which does not express ARX as previously described in mice ([@bb0280]). As ARX is a transcription factor primarily expressed in neuron nuclei, immunoreactivities appeared as brown dots within nuclei compared to blue negative-nuclei counterstained with Haematoxylin.

2.2. Neuroimaging analyses {#s0030}
--------------------------

### 2.2.1. Study participants: *ARX* patients and age- and sex-matched healthy controls {#s0035}

*ARX* patients were recruited through their primary care doctor or the specialist who asked for molecular testing. Most of the patients are followed in the National Reference Centre for Rare Diseases with Intellectual Disability (Lyon, France). After having clearly explained the goals of this study, all patients and their guardians gave their written informed consent in accordance with the Ethical Committee protocols of French Public Hospitals. Data were collected at CERMEP (Centre d\'Etude et de Recherche Multimodal Et Pluridisciplinaire) in Lyon. Molecular screening for *ARX* gene was performed in laboratories from a French network dedicated to neurogenetic testing as previously described ([@bb0285]). Age- and sex-matched healthy controls were recruited through local advertisements. Adult healthy control participants and the parents of each child included in the study signed an informed consent before the study procedure started.

Thirteen *ARX* patients and 13 age- and sex-matched healthy controls were included in the study and completed brain MRI. All *ARX* patients exhibited the same mutation in the *ARX* gene, the 24 base pair duplication (c.429_452dup24) in exon 2 resulting in a polyalanine tract expansion responsible for an insertion of 8 alanine residues in the ARX protein. Subjects having any contraindications to MRI scanning (such as cardiac pacemaker, metal clips or implants, osteosynthesis material and claustrophobia) or non-correctible visual impairment were systematically excluded. An additional exclusion criterion for healthy controls was having a history of neurological or psychiatric disorder. The mean age was 20.3 years \[6.3--40.3\] for the *ARX* patient group and 20.6 years \[7.5--42.3\] for the age- and sex-matched healthy control group. The mean Head Circumference (HC) was −0.2SD \[−1.5 to+1\] and + 0.8SD \[−1 to +2\] in the *ARX* and age- and sex-matched healthy control group respectively. All *ARX* patients had an IQ below 70. The mean adaptive global score (Vineland Adaptive Behavior Scale) in the *ARX* patient group was 44.5 \[30--59\].

In order to avoid major age-related variations in brain size and myelination, we did not include for volumetric and surface analyses, patients under the age of 10 that led us to exclude the two youngest *ARX* patients aged 6 years 4 months and 9 years 3 months old respectively and their age- and sex-matched healthy controls.

### 2.2.2. Kinematic measurements {#s0040}

A kinematic study of a grasping movement was performed in all participants, whose results have previously been published ([@bb0085]). The task consisted of reaching, grasping and lifting a plastic parallelepiped block (50 ∗ 30 ∗ 15 mm) from a specific starting point. The kinematic parameter which was the most impaired in *ARX* patients was the time to Maximum Grip Aperture (MGA) also called MGA latency when grasping the object with the thumb-annular pinch at −56° ([@bb0085]). We thus considered that this kinematic parameter was a good indicator of the motor impairment severity in *ARX* patients.

### 2.2.3. Procedures and MRI acquisition {#s0045}

Due to the unique challenges resulting from the environment of the fMRI scanner in ID patients, special attention was given to spend adequate time acclimating the patients to each aspect of the fMRI scan session experience using a mock scanner. Reassurance was necessary at each step such as helping them to feel comfortable lying on a moving bed, adjusting to the sensations of having their head within the head coil, being in a noisy environment (scanner) without being afraid, and getting used to looking into a mirror to watch a movie during data acquisition. They first watched a family member or staff member lying down in a mock scanner, to help them understand that it was painless. Then *ARX* patients were trained in a mock MRI scanner not to move. This training also decreased their anxiety. One to three sessions in the mock scanner were necessary per patient. The actual MRI session then followed. During the morphometric data acquisition (3DT1) all participants were watching a movie.

Image acquisition was performed on a 1.5 T Siemens scanner (CERMEP, Lyon). High resolution (1 × 1 × 1 mm) structural imaging with 3D T1-weighted Fast-Spoiled Gradient Recalled (FSPGR) sequence (TR/TE/TI = 1970/3.93/1100 ms, FOV = 256 × 256 mm) was obtained for each patient and age-matched healthy control. In addition, a T2 sequence was performed (51 axial slices, FOV = 220 mm, voxel size: 0.9 × 0.9 × 2.5 mm, TR/TE = 7740 /96 ms).

### 2.2.4. MRI data analysis {#s0050}

MRI images were clinically reviewed by two paediatric neurologists from the National Reference Centre for Rare Diseases with Intellectual Disability (Lyon, France). The vermian height was determined on the T1-weighted sagittal medial view of each individual. The normality of the vermian height distribution was checked using a Shapiro-Wilk normality test. A one-way ANOVA test was applied to compare differences between groups.

MRI data were processed on a Linux workstation (MGH Martinos Center, Boston, USA), using FreeSurfer software version 5.1 (<http://surfer.nmr.mgh.harvard.edu>), to reconstruct the cortical surface. FreeSurfer uses a series of computationally intensive steps on the T1-weighted structural volumes to estimate the grey/white interface ([@bb0095]; [@bb0130]; [@bb0140]). These steps include motion correction and averaging, computing Talairach transforms, intensity normalization, skull stripping, tessellation of the grey matter/white matter boundary, automated topology correction, automatic volume labelling and white matter segmentation. The accuracy of the reconstruction of pial and white matter surfaces and the subcortical segmentation were manually checked for every subject, by displaying each segmentation result (aseg.mgz file) in tkmedit. Any inaccuracies in the reconstruction of white and pial surfaces or in the subcortical segmentation of individual subject were manually corrected in each case before calculating the cortical thickness. Cortical thickness measurements were computed as the distance between the pial and white matter surfaces at each point across the cortical cortex surface. Data were then aligned according to cortical folding ([@bb0095]) and smoothed on the surface tessellation, using an iterative nearest neighbour procedure. Smoothing was restricted to the cortical surface, thus avoiding the averaging of data across sulci or outside the grey matter ([@bb0095]). This method has the advantage of matching morphologically homologous cortical areas based on the main gyri/sulci patterns with minimal metric distortion.

Group analyses were performed by resampling each subject\'s data to the FreeSurfer average atlas. Cortical thickness maps were smoothed using a Gaussian kernel with a full width half maximum of 10 mm. Vertex-wise analyses of cortical thickness were performed with FreeSurfer. A general linear model was used to compare cortical thickness between groups with one discrete factor with two classes: *ARX* patients and age-matched healthy controls. The statistical threshold was set at *p* \< 0.05, cluster-based corrected for multiple comparisons using Monte-Carlo simulation. Analyses of the relationships between cortical thickness measurements in *ARX* patients and neuropsychological data (Vineland Adaptive Behavior Scale) were performed by means of linear regression within FreeSurfer.

The automated procedure for labelling different brain structures and getting their volumetric measurements is described in detail elsewhere ([@bb0140]). This procedure assigns a neuroanatomical label to each voxel in an MRI volume based on probabilistic information automatically estimated from a manually labelled training set, including both grey and white matter. Automated segmentation and cortical parcellation with FreeSurfer has been shown to be robust and reliable in adults and children over the age of 5. It has also been performed in patient populations with known brain abnormalities. Statistical analyses of brain volumes were performed using R software (<http://www.r-project.org>). The normality of data distribution was first checked using the Shapiro and Wilk normality test. Then a between group analysis (*ARX* patients and age-matched healthy controls) was performed using an ANOVA. The statistical threshold was set at p \< 0.05, Bonferroni corrected. As we were expecting differences in brain size between *ARX* patients and healthy controls, we added an additional analysis on normalized brain volume for each Region Of Interest (ROI), by dividing each ROI volume of each subject by the intracranial volume corresponding to each subject ([@bb0260]). Correlation analyses between ROI volumes and kinematic measurement (MGA latency) within a given participant group were performed using the Pearson correlation coefficient. We used Slicer 3.4 ([http:www.slicer.org](http://www.slicer.org){#ir0020}) to build a 3D model of the basal ganglia in ARX and age- and sex-matched healthy controls.

3. Results {#s0055}
==========

3.1. ARX is strongly expressed in tangentially migrating progenitors of GABAergic neurons {#s0060}
-----------------------------------------------------------------------------------------

In the developing human brain, ARX was found mainly expressed in regions rich in GABAergic neurons such as the hippocampus (dentate gyrus), the amygdaloid complex and the thalamic reticular nucleus. ARX was also found particularly enriched in the ganglionic eminences (GE) that are the main source of GABAergic cortical interneurons and of striatal neurons ([@bb0240]; [@bb0270]). The globus pallidus and other basal ganglia related nuclei (substantia innominata and basal nucleus of Meynert) also contained numerous ARX-positive neurons. In addition, ARX was found particularly enriched in non-radially migrating neurons ([@bb0075]), such as cortical interneurons migrating from the GE, neurons of the rostral migratory stream migrating from the subventricular zone of the lateral ventricle to the olfactory bulb, and neurons of the gangliothalamic body migrating from the GE to the dorsal thalamus. Unlike cortical projection progenitors that migrate along radial-glial cell processes, these neurons rely on neurophilic interactions and migrate closely together (called chain-migration) following extracellular cues such as semaphorins to reach their final position in the brain ([@bb0075]). Towards the end of gestation, both the number of labelled cells and the level of ARX expression slowly decreased and at birth, it was only expressed in a fraction of cells in the same structures ([Table 1](#t0005){ref-type="table"}). In the adult brain, ARX was still strongly expressed in neurons of layers II and IV of the cerebral cortex as previously observed for cortical interneurons ([@bb0375]) and in the caudate nucleus, suggesting a role not only in neuronal migration and development but also in more mature neurons.

### 3.1.1. ARX expression in the developing cerebral cortex {#s0065}

During the second trimester of gestation, the cerebral cortex was very strongly labelled, especially the ventricular (VZ) and subventricular zone (SVZ) ([Fig. 1](#f0005){ref-type="fig"}A--C), suggesting a role of ARX in cortical neuronal progenitors, similarly to what has been described in mouse ([@bb0155]; [@bb0055]; [@bb0345]). In the marginal zone (MZ), several cells were positive in the transient subpial granular layer (SGL) ([Fig. 1](#f0005){ref-type="fig"}D--F, see Supplementary data). In the SVZ, as well as in the cortical intermediate zone (IZ) and subplate, many strongly positive tangentially-orientated nuclei were visible, probably corresponding to migrating interneurons coming from the medial ganglionic eminence (MGE) ([Fig. 1](#f0005){ref-type="fig"}D, G). At all early stages, strongly labelled cells were scattered in all the developing hippocampus, including Ammon\'s horn and the presumptive dentate gyrus (data not shown).Fig. 1ARX expression in the developing cortex and ganglionic eminences. At 13 weeks of gestation (WG), the dorsal telencephalon was very strongly labelled (A--B), in particular neuronal progenitors of the ventricular (VZ) and subventricular zone (SVZ), in which the vast majority of cells were ARX-positive (B--C), including dividing cells as observed with H&E and Cresyl Violet staining of the nuclei (inset, C). In the intermediate zone (IZ), approximately 40 to 50% of the cells were ARX-positive (D). In the MZ, several nuclei positive for ARX had an orientation suggestive of inward migration towards the upper part of the cortical plate (CP) (E--F). Cajal-Retzius cells were negative (E, inset). In the SVZ/IZ, several ARX-labelled cells were tangentially orientated (G). Several labelled cells were also detected in the putamen (Pu) and caudate nucleus (cn) (H). In the lateral ganglionic eminence (LGE), ARX-expressing cells were present in the ventricular zone (VZ) and inner (iSVZ) and outer subventricular zone (oSVZ) (I) whereas only rare ARX-expressing cells were present in the VZ of the medial ganglionic eminence (MGE) (J). Streams of ARX-positive post-mitotic neurons tangentially migrating around clusters of non-labelled progenitors were detected in the iSVZ (K) and oSVZ (L--M) of the MGE. SGL: subpial granular layer, Gp: globus pallidus, Th: thalamus, Hy: hypothalamus. Scale bars: A, 2 mm, B, H, 500 μm, C, 100 μm, D, I-L, 200 μm, E--G, 50 μm.Fig. 1

### 3.1.2. ARX expression in the ganglionic eminence (GE) and basal ganglia {#s0070}

GE consists of transitory brain structures that are divided anatomically into three parts, the medial (MGE), lateral (LGE) and caudal ganglionic eminence (CGE). The MGE gives rise to pallidal projection neurons and to cortical and striatal interneurons ([@bb0240]; [@bb0255]), the LGE, which is dorsal to the MGE, produces striatal projection neurons, olfactory bulb interneurons and possibly cortical interneurons and finally, the CGE generates subtypes of interneurons that are destined for cortex, hippocampus, amygdala and other limbic system nuclei, as well as caudal striatal and pallidal neurons ([@bb0045]). At all fetal stages, the GE were very strongly labelled ([Fig. 1](#f0005){ref-type="fig"}H--M), especially intermediate progenitors of the inner subventricular zone (iSVZ) ([Fig. 1](#f0005){ref-type="fig"}H--K, see Supplementary data for a more detailed description). Interestingly, although most of the neuronal stem cells composing the VZ expressed ARX in the LGE, ARX was only detected in rare cells in the VZ of the MGE ([Fig. 1](#f0005){ref-type="fig"}I--J), suggesting that neuronal stem cells have distinct identities in the MGE and LGE.

ARX was also strongly expressed in migratory streams of neurons leaving the LGE and MGE (see Supplementary data for a more detailed description of ARX expression in GE). Accordingly, several ARX-positive cells migrating from the adjacent LGE were detected at the boundary between the caudate nucleus and the LGE. Similarly, streams of ARX-expressing cells were also detected in the striatal bridges connecting caudate nucleus and putamen ([Fig. 2](#f0010){ref-type="fig"}A--C). At 32 WG, ARX-expressing cells were also detected in the nucleus accumbens which is a component of the striatum, and also a part of the limbic system ([Fig. 2](#f0010){ref-type="fig"}D).Fig. 2ARX expression in the developing subpallium. ARX expression at 16 and 18 WG (A). Outlined boxed areas are magnified in the following panels at different stages. ARX antibody labelled several cells in the caudate nucleus (cn) (B) and cells migrating towards the putamen (Pu) through the internal capsule (C). At 32 WG, several ARX-expressing cells were detected in the nucleus accumbens (na) (D). Scattered cells expressing ARX were also detected in neurons migrating from the GE towards the thalamus (Th) (E) through the gangliothalamic body (H) and in the developing hypothalamus (Hy) (F, G). At 32 WG, several ARX-expressing cells were detected in the rostral migratory stream (RMS) in the olfactory tubercle (I) ctx: cortex, LGE, MGE, CGE: lateral, medial and caudal ganglionic eminence. Scale bars: A, 5 mm, B, G, 50 μm, C, E, H, 100 μm, F, 200 μm, D, I, 1 mm.Fig. 2

### 3.1.3. ARX immunoreactivity in the diencephalon and basal telencephalic structures {#s0075}

In the developing diencephalon, ARX was absent from the VZ of the third ventricle, but strongly expressed in scattered cells of the developing thalamus ([Fig. 2](#f0010){ref-type="fig"}E), especially in the periventricular complex and the reticular nucleus, and to a lesser extent, in dorsal and ventral nuclei of the anterior complex. The ventral thalamus and hypothalamus also displayed several ARX-positive cells in close proximity to the ventricle ([Fig. 2](#f0010){ref-type="fig"}F--G). Between 22 and 32 WG, ARX expression was also identified in the gangliothalamic body ([Fig. 2](#f0010){ref-type="fig"}H), a voluminous stream of migrating bipolar neurons only observed in humans and not found in any other species, and regarded as a corridor through which neurons migrate from the GE to the dorsal thalamus ([@bb0220]; [@bb0225]).

Overall, these data suggest that ARX is particularly important for the generation and migration of GABAergic cells in the cortical plate, basal ganglia and basal telencephalic structures. After the development of these structures is completed, ARX expression is strongly decreased but is still maintained in some cells of the same structures ([Table 1](#t0005){ref-type="table"}), suggesting a role of ARX, not only during development but also in more mature neurons.

3.2. Clinical MRI analysis in *ARX* patients and age- and sex-matched healthy controls {#s0080}
--------------------------------------------------------------------------------------

No major brain malformation was found in the 13 *ARX* dup24 patients or the 13 age- and sex-matched healthy controls. Non-specific MRI features were observed in six *ARX* patients. Two *ARX* patients had a mild ventriculomegaly (lateral ventricles were 11 and 12 mm wide respectively), two had ventricular asymmetry without dilatation, one had postero-superior vermis atrophy (lobules VI and VII) associated with an enlargement of the horizontal hemispherical cerebellar fissure and one *ARX* patient had a retro-cerebellar arachnoid cyst. Dilated Virchow Robin (VR) spaces were found in all *ARX* patients along the lenticulo-striate arteries, but 8 aged-matched healthy controls also had enlarged VR spaces, a sign which is not specific. No significant difference in vermis height was found between *ARX* patients and healthy controls (mean vermis height of 47.8 mm (SD 3.3) and 47.2 mm (SD 2.5) in *ARX* patients and age- and sex-matched healthy controls respectively).

3.3. Brain volumetric analyses in *ARX* patients and age- and sex-matched healthy controls {#s0085}
------------------------------------------------------------------------------------------

Regarding global brain volumes, no significant group effect was found on intracranial volume, white matter (WM), cerebellar, corpus callosum and lateral ventricle volume when comparing *ARX* dup24 patients and age- and sex-matched healthy controls ([Table 2](#t0010){ref-type="table"}). Even after normalization by intracranial volume, *ARX* patients had similar cerebellar volume compared to age- and sex-matched healthy controls (*F*(1,20) = 0.3, *p* = 0.6), which is consistent with the absence of *ARX* expression in the developing and adult cerebellum that we observed here and that was previously reported in rodents. However, a significant group effect was found for the volume of the caudate nuclei, as well as of the hippocampi ([Table 2](#t0010){ref-type="table"}). More precisely, *ARX* dup24 patients had a significantly decreased striatal volume, mainly involving the caudate nuclei, compared to age-and sex-matched healthy controls ([Fig. 3](#f0015){ref-type="fig"}A and B). After normalization by intracranial volume, the group effect was still significant on caudate nuclei (*F*(1,20) = 7.5, *p* = 0.01). Moreover, we found a significant correlation (r^2^ = 0.46, *p* = 0.001, [Fig. 3](#f0015){ref-type="fig"}C) between the caudate nucleus volume and the degree of motor impairment quantified by the kinematic parameter which was the most impaired in *ARX* patients ([@bb0085]): the smaller the caudate nucleus volume was, the more impaired the kinematic parameter was.Table 2Brain volumetric analyses in *ARX* patients and age- and sex-matched healthy controls.Table 2Brain RegionMean VolumesStandard deviation volumesGroup effectHC*ARX*HC*ARXFp*Global Volumes Total Intracranial Volume1,711,658.51,638,059.2110,728.3137,066,71.9NS GM Volume801,400.7735,045.374,387.162,258.65.10.035 WM Volume548,929.9524,496.941,43970,714.20.98NS Brain Stem23,319.222,224.92774.61783.71.2NS Corpus Callosum Volume3365.43465.9353.1453.10.3NS Lateral Ventricule Volume10,334.418,038.63957.112,903.13.6NSCerebellum Global cerebellum Volume158,348.8153,572.318,64874330.6NS WM Volume30,097.531,240.35764.33191.70.3NS GM Volume128,251.4122,33213,856.98164.21.5NSSub-cortical Structures Caudate Volume8333.86994.5756.3953.713.30.0016 Putamen Volume12,783.111,987.514361143.22.1NS Pallidum Volume3900.43618.7505.9663.31.25NS Thalami Volume16,118.314,985.61699.91210.23.20.08 Sub-Thalami Volume8597.178771001.0720.53.750.06 Hippocampus9435.78592.9534.1775.58.80.007 Amygdala3679.53346.8477.7368.53.3NS[^8]Fig. 3Basal ganglia volume analysis in *ARX* patients and age- and sex-matched healthy controls. A: Normalized caudate volume in *ARX* patients and age- and sex-matched healthy control subjects showing significantly decreased volume in *ARX* patients (\*\*\*: *p* \< 0.005); B: 3D modelization of the basal ganglia clearly shows the decreased volume of the caudate nucleus (light blue) in *ARX* patients compared to age- and sex-matched healthy controls; C: Correlation between caudate nucleus volume and the kinematic parameter. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)Fig. 3

We also observed a significant decrease of the hippocampal volume in *ARX* patients compared to age- and sex-matched healthy controls. We observed a decreased volume of thalamic and sub-thalamic nuclei in *ARX* patients compared to age- and sex-matched healthy controls, but this did not reach significance (it was only a trend, likely by lack of power in this study on a rare disease, [Table 2](#t0010){ref-type="table"}). We found no correlation between the volume of thalamic and sub-thalamic nuclei and the severity of motor impairment (r^2^ = 0.09, *p* = 0.82 and r^2^ = 0.44, *p* = 0.24 for thalamic and sub-thalamic nuclei respectively).

Interestingly, we also found a slight but significant decrease of the hemispheric grey matter volumes in *ARX* dup24 patients ([Table 2](#t0010){ref-type="table"}), suggesting that they may have a small global decreased number of neurons, which is consistent with the expression of ARX in both glutamatergic and GABAergic neuronal progenitors and the observed microcephaly in both mouse and human patients with severe loss-of-function mutations of *ARX* ([@bb0035]; [@bb0210]).

3.4. Cortical thickness analysis in *ARX* patients and age- and sex-matched healthy controls {#s0090}
--------------------------------------------------------------------------------------------

We observed that the precentral gyrus, a part of the primary motor cortex, was significantly and bilaterally thinner in the *ARX* patient group compared with the age- and sex-matched healthy control group ([Table 3](#t0015){ref-type="table"}, [Fig. 4](#f0020){ref-type="fig"}). In addition, the correlation between precentral gyrus cortical thickness and caudate volume was significant (r^2^ = 0.57, *p* = 0.005 and r^2^ = 0.50, *p* = 0.019 on the right and left hemisphere respectively). More precisely, the smaller the caudate nucleus was, the thinner the precentral cortical thickness was. This suggests that together with the decreased volume of the caudate nuclei, these morphometric findings very likely explain the specific motor phenotype observed in *ARX* dup24 patients.Table 3Areas of significant cortical thinning in *ARX* dup24 patients compared with age-matched healthy controls.Table 3Cluster sizeBrain regionHemisphereMNI coordinates*p* value (CWP)(\# Vertex)*xyz*3225Precentral GyrusLeft−18.3−22.571.40.01673035Precentral GyrusRight47.32.730.80.0106[^9][^10]Fig. 4Mean thickness difference significance maps. Lateral and medial inflated views of the brain showing areas presenting cortical thinning in the ARX patient group compared with age-matched healthy control group (A: left lateral inflated view, B: right lateral inflated view, C: left medial inflated view, D: right medial inflated view).Fig. 4

A significant association was also found within the *ARX* patient group between cortical thinning and the Vineland Adaptive Behavior scale in prefrontal cortex bilaterally: the thinner the prefrontal cortex was, the lower the Vineland scale was ([Fig. 5](#f0025){ref-type="fig"}), suggesting that prefrontal cortex decreased thickness may be related to the ID observed in these patients. Anatomical studies in primates have shown that the caudate and anterior putamen receive afferents from dorsal lateral prefrontal regions and pre-SMA ([@bb0360]). We thus also analyzed the correlation between prefrontal cortical thickness and caudate volume, which was significant (r^2^ = 0.68, *p* = 0.0005 and r^2^ = 0.58, *p* = 0.004 on left and right hemisphere respectively). More precisely, the thinner the prefrontal cortical thickness was, the smaller the caudate was.Fig. 5Correlation between cortical thickness and the Vineland Adaptive Behavior scale. A and B: Cortical brain maps showing the significant association between cortical thinning and the Vineland Adaptive Behavior scale within the *ARX* patient group; C: Correlation between the cortical thickness of the Left prefrontal region and the Vineland scale (r^2^ = 0.86, *p* = 0.0006); D: Correlation between the cortical thickness of the Right prefrontal region and the Vineland scale (r^2^ = 0.85, *p* = 0.0009).Fig. 5

4. Discussion {#s0095}
=============

In this study, we report for the first time ARX expression in the human developing and adult brain and describe a specific neuroanatomical pattern associated to *ARX* dup24 that very likely represents the substrate of the peculiar developmental Limb Kinetic Apraxia (LKA) observed in these patients.

4.1. *ARX* expression in progenitors of GABAergic neurons {#s0100}
---------------------------------------------------------

Although there are many differences in brain development between rodents and humans, especially regarding the number and complexity of interneurons, we observed that ARX pattern of expression in human fetal brain is approximately similar and concordant with what has been previously reported in rodents ([@bb0245]; [@bb0210]; [@bb0065]; [@bb0280]; [@bb0050]; [@bb0150]; [@bb0155]). We found that during development, the most strongly labelled structures were the germinal zone of dorsal telencephalon, the cortical plate and the GE ([Table 1](#t0005){ref-type="table"}). In addition to the caudate nucleus and putamen, several strongly ARX-positive cells were also identified in the nucleus accumbens, in the pallidum and related nuclei such as substantia innominata and basal nucleus of Meynert. All these data suggest that similarly to rodents, the GE contributes to GABAergic neuron production for the striatum and the limbic system ([@bb0240]; [@bb0255]; [@bb0290]; [@bb0195]) and that ARX is required for the development of these structures. In addition, ARX was found to be strongly expressed in many cortical neurons using a non-radial mode of migration based on neurophilic interactions, confirming that ARX may play a role in this type of migration as previously suggested by experiments in which Arx overexpression in cortical progenitors was sufficient to induce tangential dispersion of immature projection neurons in mouse cerebral cortex ([@bb0155]; [@bb0145]).

In conclusion, we observed the strongest expression of *ARX* between 12 and 22 GW. Then during the third trimester of gestation, both the number of labelled cells and the level of *ARX* expression slowly decreased ([Table 1](#t0005){ref-type="table"}). In our adult case, it was only expressed in a few cells such as neurons of layers I, II and IV of the cerebral cortex, as previously observed for cortical interneurons ([@bb0375]) and in the caudate nucleus, arguing for a role of ARX in mature neuron functioning of these structures. We then used MRI to investigate the consequences for adult patients of a defect in the function of this gene during brain development.

4.2. Brain anatomical structure changes in *ARX* patients {#s0105}
---------------------------------------------------------

As we recently described a recognizable phenotype with a specific motor impairment in *ARX* dup24 patients ([@bb0085]), we decided to further characterize potential neuro-anatomical distinctive patterns associated with this mutation using high quality morphometric MRI data analyzed with FreeSurfer software. This automated procedure has already been validated using both neuropathology approaches performed on human post-mortem brain ([@bb0315]), and manual measurements on human brain MRI ([@bb0320]). We show here that *ARX* patients have a significantly decreased striatal volume especially the caudate nuclei, and to a lesser extent of the thalamic and sub-thalamic nuclei, associated to a decrease in cortical thickness of the precentral gyrus and hippocampus. Interestingly, the implication of basal ganglia in the pathophysiology of ARX-related phenotypes has already been suggested in the literature. Histopathological studies on XLAG (X-linked Lissencephaly with Abnormal Genitalia) human patients have revealed poorly delineated and atrophic basal ganglia with small fragmented caudate nuclei ([@bb0035]). Moreover, Colombo et al. have reported functional impairment of the basal ganglia morphogenesis in *Arx* knock-out mice ([@bb0070]). It is therefore conceivable that *ARX* dup24 mutation responsible for a partial loss-of-function can lead to subtle defects in the development and differentiation of basal ganglia, which may be visible only by using high quality morphometric MRI technology.

This hypothesis is further reinforced by the fact that basal ganglia are known to regulate sensorimotor processing and are especially involved in precision grip force control ([@bb0300]; [@bb0365]), a function that is altered in *ARX* dup24 patients who present a very peculiar impairment of upper limb distal motor function with a pathognomonic hand-grip, similarly to the distortion of individual finger movements and posture observed in LKA. This particular "reach and grip" was not found in a group of age- and IQ-matched Down Syndrome (DS) patients who served as controls to ensure this was not related to low-cognitive functioning ([@bb0085]). Precision grip control requires precise and fine manipulation of the forces applied to the object being gripped ([@bb0300]). During a gripping task, the following brain regions are active: primary sensorimotor cortex, dorsolateral premotor cortex, cerebellum and basal ganglia. The motor cortex and the basal ganglia allow the programming, selection and execution of movements. They act in concert owing to the close connections between the two structures. Information coming from the premotor and motor cortices is transmitted to the basal ganglia, mainly the striatum, which selects and activates motor planning allowing the proper motor activity and inhibits aberrant motor planning. In healthy controls, precision grip force tasks lead to increased activity in all basal ganglia ([@bb0300]). Interestingly, an fMRI study showed that caudate nuclei are involved in selecting the amplitude of force contractions ([@bb0360]). Anterior nuclei in the basal ganglia such as caudate and anterior putamen are involved in the predictive scaling of precision grip force control ([@bb0365]). Specific anterior nuclei of the basal ganglia are thus involved in planning aspects of precision grip force, whereas more posteriorly located nuclei (such as subthalamic nuclei and internal portion of the globus pallidus) are involved in dynamic parameters of grip force output ([@bb0360]; [@bb0300]; [@bb0365]). There are many movement disorders that arise as a result of basal ganglia dysfunction (Parkinson disease, dystonia, Huntington disease...) ([@bb0300]; [@bb0350]).

DS patients have been shown to have relatively preserved basal ganglia which appear to be enlarged by comparison with the overall cerebral brain reduction in DS patients ([@bb0275]; [@bb0370]; [@bb0325]). This suggests that the combined decrease in cortical thickness of the primary motor cortex and basal ganglia volume we identified in *ARX* dup 24 patients may be considered as a hallmark of the disease and is likely to be the substrate of their specific motor phenotype. The smaller the caudate was, the thinner the precentral cortical thickness was. This hypothesis is further strengthened by the significant correlation observed between the volume of the caudate nucleus and the degree of motor impairment quantified by kinematic parameters of the precision grip in *ARX* patients. In the most severe forms associated with *ARX* dup24 mutation (Partington syndrome) major hand dystonia was observed, but mild to moderate focal dystonia (while holding a pen) was observed in 74% of the *ARX* patients ([@bb0085]). It is interesting to note that dystonia is not related to the dysfunction of one single brain region, but rather involves a motor network including basal ganglia, cerebellum, thalamus and sensorimotor cortex ([@bb0200]). We can probably here exclude cerebellum as we did not find any difference in cerebellum volume comparing *ARX* patients to age- and sex-matched healthy controls, an observation which is consistent with the absence of *ARX* expression in the developing and adult cerebellum. But we did find changes in the other nodes of this motor network. It would also be very interesting to study the structural and functional connectivity between these nodes ([@bb0250]; [@bb0200]; [@bb0230]).

In addition to the significant decrease observed in striatal volume, we also observed a decrease of thalamic and sub-thalamic nuclei volumes. Nevertheless, we did not find any relationship between the decreased thalamic volume and motor impairment. Importantly, the GE has been shown to contribute neurons to the thalamic nuclei in humans ([@bb0220]; [@bb0225]). These cells migrate through the gangliothalamic body, a unique transient structure observed only in humans and present from 15 to 34 WG, followed by a progressive decrease from 34 WG. Phylogenetically, it is striking to note that this neuronal migrating pattern is unique to human. It has not been found in any other species including monkeys, in which all cells of dorsal thalamus come exclusively from the diencephalon. The gangliothalamic body is a stream of migrating bipolar neurons which rely on homotypic-neurophilic guidance, eventually form GABAergic neurons in the pulvinar and in the dorsal as well as mediodorsal subnuclei of the thalamus, which are anatomically related to both primary and associative cortical areas involved in higher cognitive functions, including symbolic reasoning or language ([@bb0225]). It is interesting to note that a thalamus volume decrease has been found in other X-linked ID such as *Rab-GDI* mutated patients ([@bb0080]), suggesting that this distinctive feature could also contribute to ID. On the contrary, increased thalamic volume has been reported in Fragile X syndrome patients ([@bb0310]; [@bb0115]; [@bb0165]), showing that the relationship between thalamus volume and ID remains unclear but it could offer new avenues to be explored. Recently, Sunnen et al. reported that *Arx* knock-out mice lost expression of specific markers of the thalamic reticular nucleus, which is entirely composed of GABAergic neurons, and of the zona incerta, an important pathway to the reticular nucleus of the thalamus, confirming a role of ARX in the development of these thalamic subnuclei ([@bb0355]).

We also observed an association between the Vineland Adaptive Behavior scale in *ARX* patients and their cortical thickness. The thinner the prefrontal cortex was, the more impaired the Vineland Adaptive Behavior scale was. It has been shown in typically developing children and adolescents that the profile of prefrontal cortical thickness maturation is closely related to the level of intelligence ([@bb0335]) and that the activation of the prefrontal cortex during task correlates with intelligence in healthy subjects ([@bb0110]; [@bb0170]). Moreover, Fragile X syndrome patients have decreased frontal lobe volume ([@bb0185]), aberrant maturation of the prefrontal cortex during adolescence ([@bb0040]) and atypical fronto-striatal circuitry ([@bb0010]; [@bb0180]), all associated with their executive functioning deficit ([@bb0160]). It has been suggested that ID patients could have a specific impairment in executive functioning ([@bb0100]; [@bb0105]). We recently showed that *ARX* patients were more impaired by inhibition (one main component of executive functioning) than their respective mental-age matched healthy controls in a visual analogical reasoning task ([@bb0090]). Our data are in concordance with this hypothesis, as the prefrontal cortex thinning is associated with weaker adaptive skills in *ARX* patients, reflecting the level of ID. Furthermore, in addition to the role in motor processes, basa ganglia have recently been shown to be also involved in cognitive (working memory, and executive functions), and affective (emotion and reward) processes ([@bb0005]). Interestingly, we found a correlation between the prefrontal cortical thinning and the caudate volume: the thinner the prefrontal cortical thickness was, the smaller the caudate was. It is possible that the basal ganglia alteration in ARX patients contributes to their cognitive phenotype.

5. Conclusion {#s0110}
=============

This study is the first to describe ARX expression in human brain at different developmental stages and the consequences of *ARX* dup24 mutation in human using quantitative MRI *in vivo*. It demonstrates that MRI is a powerful tool for the study of neuroanatomical profiles in rare diseases with ID. It would be very interesting in the future to replicate this structural study on a larger population of patients and at higher magnetic field, and to add functional MRI acquisition to better characterize the spatial and temporal patterns of brain activity in this patient population. Taken together, our findings confirm the key role of ARX in the generation, migration and function of GABAergic neurons both in the cerebral cortex, the basal ganglia and thalamus, providing some insights to explain the peculiar motor phenotype observed in *ARX* dup24 patients. It would be very interesting to further characterize the corticobasal networks structural connectivity by using diffusion MRI.
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**Supplementary data:** Description of ARX expression in the developing human brain;**Supplementary Table 1:** Age and cause of death of selected autopsy cases.Image 1

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.nicl.2018.04.001>.
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